Press Releases

All Releases
View Summary Myriad Genetics' HRD Test Predicts Response to Platinum Therapy in Triple-Negative Breast Cancer
Dec 7, 2012
PDF 61.2 KB Add to Briefcase
View Summary Supreme Court of the United States to Hear Isolated DNA Patent Case
Nov 30, 2012
PDF 19.1 KB Add to Briefcase
View Summary Myriad Genetics' Prolaris Test Predicts Biochemical Recurrence in Prostate Cancer Patients Following Radiation Therapy
Nov 28, 2012
PDF 16.0 KB Add to Briefcase
View Summary Myriad Genetics to Present at the Piper Jaffray Healthcare Conference
Nov 15, 2012
PDF 12.0 KB Add to Briefcase
View Summary Myriad Genetics Reports First Quarter Fiscal Year 2013 Results
Nov 5, 2012
PDF 23.9 KB Add to Briefcase
View Summary Myriad Genetics to Present at the 2012 Credit Suisse Annual Healthcare Conference
Nov 1, 2012
PDF 12.0 KB Add to Briefcase
View Summary Myriad Genetics to Announce First Fiscal Quarter 2013 Results on Monday, November 5, 2012
Oct 15, 2012
PDF 12.2 KB Add to Briefcase
View Summary Myriad's HRD Score Detects Loss of DNA Repair Function in Ovarian Cancer
Oct 10, 2012
PDF 15.3 KB Add to Briefcase
View Summary Myriad Genetics Sponsors Cancer Awareness Initiatives in Support of National Hereditary Breast and Ovarian Cancer Week
Oct 3, 2012
PDF 16.2 KB Add to Briefcase
View Summary Noridian Notifies Myriad of Initial Draft Decision to Classify Prolaris(R) as a Non-Covered Service
Sep 24, 2012
PDF 15.6 KB Add to Briefcase
View Summary Myriad Genetics to Present at the Morgan Stanley Global Healthcare Conference
Aug 30, 2012
PDF 11.5 KB Add to Briefcase
View Summary U.S Court of Appeals Upholds Myriad's Gene Patents
Aug 16, 2012
PDF 15.8 KB Add to Briefcase
View Summary Myriad Genetics Reports Fourth Quarter and Fiscal Year 2012 Results
Aug 14, 2012
PDF 26.4 KB Add to Briefcase
View Summary Myriad Genetics and Pharma Mar Enter Into Companion Diagnostic Agreement
Jul 26, 2012
PDF 15.7 KB Add to Briefcase
View Summary Myriad Genetics to Announce Fiscal Fourth Quarter and Fiscal Year 2012 Results on Tuesday, August 14, 2012
Jul 24, 2012
PDF 12.3 KB Add to Briefcase
View Summary Myriad Genetics Receives the Charles R. Smart Visionary Award From the American Cancer Society(R)
Jun 6, 2012
PDF 14.5 KB Add to Briefcase
View Summary Myriad's Lung Cancer Prognosis Test Shown to Significantly Predict Survival in Early Stage Lung Cancer Patients
Jun 4, 2012
PDF 15.3 KB Add to Briefcase
View Summary Myriad Genetics to Present at Upcoming Investor Conferences in June
May 22, 2012
PDF 11.7 KB Add to Briefcase
View Summary Myriad Genetics Announces Presentation of Lung Cancer Study at American Society for Clinical Oncology Annual Meeting
May 16, 2012
PDF 15.0 KB Add to Briefcase
View Summary Myriad RBM Announces the Launch of OncologyMAP® v. 2.0
May 9, 2012
PDF 16.3 KB Add to Briefcase
Showing 61-80 of 293 Page: 1 2 3 4 5 6 7 8 ... 15  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

Stock Quote (NASDAQ:MYGN)

Price:
37.97
Change:
- 0.36
Open:
38.41
Previous Close:
38.33
Day High:
38.98
Day Low:
37.62
52 Week High:
42.50
52 Week Low:
20.02
Volume:
2,031,300
4:00 PM ET on Apr 17, 2014
Delayed at least 20 minutes.
Provided by eSignal.

Investor Contact

Scott Gleason
(801) 584-1143
sgleason@myriad.com

Media Contact

Ron Rogers
Corporate Communications and Media Relations
(801) 584-3065
rrogers@myriad.com